scispace - formally typeset
Journal ArticleDOI

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Björn Dahlöf, +14 more
- 23 Mar 2002 - 
- Vol. 359, Iss: 9311, pp 995-1003
TLDR
Losartan prevents more cardiovascular morbidity and death than atenolol for a similar reduction in blood pressure and is better tolerated, while new-onset diabetes was less frequent with losartan.
About: 
This article is published in The Lancet.The article was published on 2002-03-23. It has received 5380 citations till now. The article focuses on the topics: Angiotensin II & Atenolol.

read more

Citations
More filters
Journal ArticleDOI

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Aram V. Chobanian, +10 more
- 21 May 2003 - 
TL;DR: The most effective therapy prescribed by the most careful clinician will control hypertension only if patients are motivated, and empathy builds trust and is a potent motivator.
Journal ArticleDOI

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

Aram V. Chobanian, +10 more
- 01 Dec 2003 - 
TL;DR: In those older than age 50, systolic blood pressure of greater than 140 mm Hg is a more important cardiovascular disease (CVD) risk factor than diastolic BP, and hypertension will be controlled only if patients are motivated to stay on their treatment plan.
Journal ArticleDOI

2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

Giuseppe Mancia, +89 more
- 21 Jul 2013 - 
TL;DR: In this article, a randomized controlled trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly people was presented. But the authors did not discuss the effect of the combination therapy in patients living with systolic hypertension.
Journal ArticleDOI

2007 Guidelines for the Management of Arterial Hypertension : The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

Giuseppe Mancia, +15 more
- 01 Jun 2007 - 
TL;DR: 2007 Guidelines for the Management of Arterial Hypertension : The Task Force for the management of Arterspertension of the European Society ofhypertension (ESH) and of theEuropean Society of Cardiology (ESC).
Journal ArticleDOI

Inflammation in atherosclerosis

Peter Libby
- 19 Dec 2002 - 
TL;DR: The new appreciation of the role of inflammation in atherosclerosis provides a mechanistic framework for understanding the clinical benefits of lipid-lowering therapies and unravelling the details of inflammatory pathways may eventually furnish new therapeutic targets.
References
More filters
Journal ArticleDOI

Electrocardiographic identification of left ventricular hypertrophy: Test performance in relation to definition of hypertrophy and presence of obesity

Peter M. Okin, +3 more
- 01 Jan 1996 - 
TL;DR: The Cornell product provides the best combination of overall accuracy and low variability of performance between definitions of hypertrophy, and has important implications for the clinical and epidemiologic use of 12-lead ECG criteria for the detection of left ventricularhypertrophy.
Journal ArticleDOI

Left ventricular hypertrophy and angiotensin II antagonists.

Björn Dahlöf
- 01 Feb 2001 - 
TL;DR: Clinical evidence shows significant efficacy in reversing left ventricular hypertrophy in hypertensive patients after treatment with angiotensin II antagonists, a relatively new class of antihypertensive agents.
Journal ArticleDOI

Experimental and clinical evidence that angiotensin II is an independent risk factor for cardiovascular disease.

Hans R. Brunner
- 19 Apr 2001 - 
TL;DR: The utility of angiotensin receptor antagonists in the treatment of chronic renal failure has been demonstrated, and the results of ongoing clinical trials can be expected to prove their benefit in other cardiovascular pathologies.
Journal ArticleDOI

Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study

Sverre E. Kjeldsen, +13 more
- 01 Aug 2000 - 
TL;DR: The successful lowering of blood pressure during 12 months of follow-up in a large cohort of patients with hypertension and LVH on ECG is demonstrated, but the need for two or more drugs to control high blood pressure in most of these patients is emphasized.
Journal ArticleDOI

Clinical data management.

R. K. Ausman, +6 more
- 16 Dec 2006 - 
TL;DR: The project is designed primarily to create a laboratory environment in which to seek a better understanding of the problems associated with medical records automation, and program and operate a system of relatively small proportions.
Related Papers (5)

Effects of an angiotensin-converting -enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

Salim Yusuf, +5 more
- 20 Jan 2000 - 

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)

Curt D. Furberg, +56 more
- 18 Dec 2002 - 

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Aram V. Chobanian, +10 more
- 21 May 2003 - 

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Barry M. Brenner, +9 more
- 20 Sep 2001 - 

Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes

Edmond J Lewis, +9 more
- 20 Sep 2001 -